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COVID-19 vaccine hesitancy in a representative working-age 
population in France: a survey experiment based on vaccine 
characteristics
Michaël Schwarzinger, Verity Watson, Pierre Arwidson, François Alla, Stéphane Luchini
Summary
Background Opinion polls on vaccination intentions suggest that COVID-19 vaccine hesitancy is increasing worldwide; 
however, the usefulness of opinion polls to prepare mass vaccination campaigns for specific new vaccines and to 
estimate acceptance in a country’s population is limited. We therefore aimed to assess the effects of vaccine 
characteristics, information on herd immunity, and general practitioner (GP) recommendation on vaccine hesitancy 
in a representative working-age population in France.
Methods In this survey experiment, adults aged 18–64 years residing in France, with no history of SARS-CoV-2 
infection, were randomly selected from an online survey research panel in July, 2020, stratified by gender, age, 
education, household size, and region and area of residence to be representative of the French population. Participants 
completed an online questionnaire on their background and vaccination behaviour-related variables (including past 
vaccine compliance, risk factors for severe COVID-19, and COVID-19 perceptions and experience), and were then 
randomly assigned according to a full factorial design to one of three groups to receive differing information on herd 
immunity (>50% of adults aged 18–64 years must be immunised [either by vaccination or infection]; >50% of adults 
must be immunised [either by vaccination or infection]; or no information on herd immunity) and to one of two 
groups regarding GP recommendation of vaccination (GP recommends vaccination or expresses no opinion). 
Participants then completed a series of eight discrete choice tasks designed to assess vaccine acceptance or refusal 
based on hypothetical vaccine characteristics (efficacy [50%, 80%, 90%, or 100%], risk of serious side-effects [1 in 10 000 
or 1 in 100 000], location of manufacture [EU, USA, or China], and place of administration [GP practice, local 
pharmacy, or mass vaccination centre]). Responses were analysed with a two-part model to disentangle outright 
vaccine refusal (irrespective of vaccine characteristics, defined as opting for no vaccination in all eight tasks) from 
vaccine hesitancy (acceptance depending on vaccine characteristics).
Findings Survey responses were collected from 1942 working-age adults, of whom 560 (28·8%) opted for no vaccination 
in all eight tasks (outright vaccine refusal) and 1382 (71·2%) did not. In our model, outright vaccine refusal and 
vaccine hesitancy were both significantly associated with female gender, age (with an inverted U-shaped relationship), 
lower educational level, poor compliance with recommended vaccinations in the past, and no report of specified 
chronic conditions (ie, no hypertension [ for vaccine hesitancy] or no chronic conditions other than hypertension [ for 
outright vaccine refusal]). Outright vaccine refusal was also associated with a lower perceived severity of COVID-19, 
whereas vaccine hesitancy was lower when herd immunity benefits were communicated and in working versus non-
working individuals, and those with experience of COVID-19 (had symptoms or knew someone with COVID-19). For 
a mass vaccination campaign involving mass vaccination centres and communication of herd immunity benefits, our 
model predicted outright vaccine refusal in 29·4% (95% CI 28·6–30·2) of the French working-age population. 
Predicted hesitancy was highest for vaccines manufactured in China with 50% efficacy and a 1 in 10 000 risk of 
serious side-effects (vaccine acceptance 27·4% [26·8–28·0]), and lowest for a vaccine manufactured in the EU with 
90% efficacy and a 1 in 100 000 risk of serious side-effects (vaccine acceptance 61·3% [60·5–62·1]).
Interpretation COVID-19 vaccine acceptance depends on the characteristics of new vaccines and the national 
vaccination strategy, among various other factors, in the working-age population in France.
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On March 11, 2020, WHO declared the SARS-CoV-2 
outbreak in China to be a pandemic. In the spring of 2020, 
all European countries implemented physical distancing 
measures as an emergency response to contain COVID-19 
and its associated death toll,1,2 especially in older adults.3–5 
As a second wave of SARS-CoV-2 infections hit Europe in 
the autumn of 2020, all countries increased the physical 
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distancing measures that had been relaxed over the 
summer months.2 Such stop-and-go strategies are likely to 
remain in place until herd immunity is reached and 
SARS-CoV-2 can no longer circulate (ie, 60% or more 
of a country’s population is immune to SARS-CoV-2 
following infection or vaccination).4,6 Because physical 
distancing measures aim to reduce SARS-CoV-2 trans-
mission to the lowest levels,1,4,7 herd immunity can only be 
achieved by mass vaccination.6,8
As of Jan 6, 2021, two COVID-19 vaccines with greater 
than 90% efficacy to reduce symptomatic infection risk9,10 
have been approved in the EU, and 16 candidate vaccines 
are in phase 3 trials.11 However, COVID-19 vaccine 
hesitancy might represent a major hurdle to achieving 
herd immunity.6,8 In a systematic review of 126 surveys 
on COVID-19 vaccination intentions, including 23 aca-
demic studies and 103 opinion polls published before 
November, 2020, Lin and colleagues showed that 
COVID-19 vaccine hesitancy is increasing worldwide.12 
Intent to receive COVID-19 vaccination varies sub stantially 
across countries,12 with France recording the lowest rate 
among European countries,13 and is generally lower in the 
working-age population than in older people. Most people 
who intend not to be vaccinated report being worried about 
the safety of new COVID-19 vaccines.12
Although opinion polls highlight the issue of COVID-19 
vaccine hesitancy, they are of limited use to prepare mass 
vaccination campaigns. Opinion polls ask about vaccina-
tion intentions, but responses depend on the framing of 
the question and are provided for unspecified vaccines.12 
New vaccines differ on various characteristics.11 Higher 
vaccine efficacy or safety is expected to be associated with 
decreased hesitancy.12 The country of manufacture of the 
vaccine11 can be associated with increased hesitancy 
because people might perceive candidate vaccines to have 
been developed hastily in the USA,12,14,15 or might distrust 
vaccines developed in China or Russia.12,16,17 Mass vaccina-
tion centres might be the only place where vaccines 
can be administered because of logistical or cold storage 
constraints, but might also increase hesitancy.18 In 
addition, estimating vaccination intentions depends on 
the granularity of responses,12 but outright vaccination 
refusal is seldom disentangled from vaccine hesitancy in 
analyses.19 The antivaccine move ment could be influ-
ential in the context of COVID-1914–16,20 and disrupt mass 
vaccination campaigns, as in 2009 for vaccinations 
against influenza A(H1N1)pdm09.18,21
This study investigates COVID-19 vaccine acceptance 
and its determinants in a representative working-age 
population (aged 18–64 years) in France. Understanding 
Research in context
Evidence before this study
Following the PRISMA guidelines, a systematic search was done 
using OVID to identify all studies on COVID-19 vaccination 
intentions published in English from Jan 1 to Dec 31, 2020, on 
MEDLINE, Embase, and PsycINFO. One systematic review was 
identified using a combination of search terms (COVID-19 OR 
SARS-CoV-2) AND (vaccine OR immunization) AND (survey OR 
poll). Based on 126 surveys published before November, 2020, 
this review showed that COVID-19 vaccine hesitancy is 
increasing worldwide. However, the usefulness of these surveys 
to inform the preparation of mass vaccination campaigns is 
limited, as vaccination intentions depend on the framing of the 
question and are provided for an unspecified vaccine. 
Multiple new COVID-19 vaccines have been developed that 
differ on various characteristics, and it is not clear which, if any, 
of the available or possible vaccines people have in mind when 
completing the survey. Furthermore, vaccination intentions 
depend on the granularity of the proposed responses and 
outright vaccination refusal is seldom disentangled from 
vaccine hesitancy in the analysis, even though the antivaccine 
movement might be influential in the context of COVID-19.
Added value of this study
In this survey experiment, COVID-19 vaccination intentions 
were assessed from repeated choice tasks among vaccines with 
varying specified characteristics, while background information 
on vaccination was controlled for. Accordingly, we developed a 
behavioural model that allowed outright vaccination refusal 
(ie, serial refusal of vaccines regardless of vaccine characteristics) 
to be disentangled from vaccine hesitancy (ie, vaccine 
acceptance that depends on vaccine characteristics). This survey 
experiment shows that COVID-19 vaccine acceptance depends 
on the new vaccines’ characteristics and the national vaccination 
strategy, among many other factors. As of early July, 2020, the 
behavioural model predicted that 29·4% (95% CI 28·6–30·2) of 
the French population of working age would refuse COVID-19 
vaccination outright in mass vaccination centres despite the 
communication of herd immunity benefits. Furthermore, 
COVID-19 vaccine acceptance in this population ranged from 
27·4% (26·8–28·0; for new vaccines manufactured in China, 
with 50% efficacy and a 1 in 10 000 risk of serious side-effects) 
to 61·3% (60·5–62·1; for new vaccines manufactured in the EU, 
with 90% efficacy and a 1 in 100 000 risk of serious side-effects).
Implications of all the available evidence
COVID-19 vaccine hesitancy seems to be increasing as mass 
vaccination campaigns draw closer in the working-age 
population. Anti-COVID-19 vaccination behaviour should be 
closely monitored as it could disrupt COVID-19 vaccination 
campaigns as happened in 2009 with vaccinations against 
influenza A(H1N1)pdm09. If the objective of a national 
vaccination strategy becomes herd immunity in the adult 
population rather than self-protection in older adults and 
patients with underlying chronic conditions, our results suggest 
that it would be more successful in France with COVID-19 
vaccines made in the EU and a communication strategy 
emphasising the collective benefits of herd immunity in the 
working-age population.
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the determinants of COVID-19 vaccine acceptance in this 
group is important because it accounts for the majority of 
the French population, and herd immunity can only be 
reached if the mass vaccination campaign is successful in 
this group. It is not certain that vaccination uptake will be 
sufficient in this group given their lower risk of a severe 
form of COVID-19 and their low rate of compliance with 
seasonal influenza vaccination programmes compared 
with older adults (aged ≥65 years).22
In contrast to opinion polls, this study used a large-scale 
survey experiment in which vaccination intentions were 
assessed from repeated choice tasks among vaccines with 
varying characteristics, while controlling for background 
information on vaccination. This method allows precise 
estimation of outright vaccination refusal and vaccine 
accep tance for a range of realistic scenarios in a mass 
vaccina tion campaign. Furthermore, differences in behav-
iour across age categories were assessed with regard 




We did a cross-sectional survey among a representative 
sample of 2000 adults aged 18–64 years in France. The 
survey was fielded around 3 weeks after the first lockdown 
was lifted on June 2, 2020.2 Participants were selected 
from an online survey research panel, which was 
developed and is maintained by the opinion survey 
research firm BVA (Paris, France) and consists of more 
than 700 000 French adults. Pre-existing information on 
the participants was used by BVA to determine eligibility 
and draw a stratified random sample, with oversampling 
of participants with low response rates. Sampling was 
stratified to match French official census statistics for 
gender, age, education, household size, area of residence 
(urban vs rural), and geographical region of residence 
(appendix p 2).
Participants completed a self-reported online question-
naire that elicited background information (including the 
stratification variables listed above) as well as informa-
tion on vaccination behaviour: working status, whether 
they were a health-care worker, vaccination behaviour in 
the past, risk factors for a severe form of COVID-19 
(current pregnancy, smoking status, body-mass index, 
hypertension, or a chronic condition other than 
hypertension), COVID-19 experience (had COVID-19 
symptoms, had a test for SARS-CoV-2 infection, or knew 
someone who had COVID-19), and risk perceptions about 
COVID-19 severity (appendix p 3). Chronic conditions 
included in the survey were diabetes, asthma, other 
chronic lung disease, chronic arterial disease, chronic 
heart disease, chronic kidney disease, and cancer. In 
accordance with eligibility criteria for phase 3 vaccine 
trials,9,10 participants who reported previous SARS-CoV-2 
infection were excluded from the survey experiment 
(appendix p 4).
The data management of BVA is approved by the 
French National Commission for Data Protection in 
accordance with the General Data Protection Regulation 
of the EU (approval renewed on May 25, 2018). The 
survey experiment followed all requirements under 
French regulations.
Survey experiment
The survey experiment consisted of two sections at the 
end of the online questionnaire: background information 
on COVID-19 vaccination, and the elicitation of vaccine 
acceptance based on vaccine characteristics.
In the first section, all participants were provided with a 
full page presenting general information about COVID-19 
vaccination (appendix p 6). In addition, each participant 
was randomly allocated by use of a random number 
generator to two different information blocks according to 
a full factorial design, with stratification by gender and 
edu cational level (some high school vs high school or 
university gradu ate). In block 1, participants were randomly 
assigned (1:1:1) to receive information about the collec tive 
benefits of herd immunity with a varying herd immunity 
target: more than 50% of adults aged 18–64 years old must 
be immu nised (either by vaccination or infection); more 
than 50% of adults must be immunised (either by vaccina-
tion or infection); or no information on herd immunity.24 
In block 2, participants were randomly assigned (1:1) to 
receive differing general practitioner (GP) advice about 
COVID-19 vaccination: recommendation or no opinion.18
In the second section, COVID-19 vaccine acceptance was 
elicited with use of a discrete choice experiment, in which 
participants completed a series of choice tasks based on 
vaccine characteristics.25 The hypothetical vaccines differed 
on four characteristics: vaccine efficacy to reduce the 
infection risk (50%, 80%, 90%, or 100%);26 vaccine safety in 
terms of the risk of serious side-effects (1 in 10 000 or 
1 in 100 000 vaccinated people); vaccine manufacturer 
(headquarters in the EU, USA, or China); and where 
vaccina tions are given (GP practice, local pharmacy, or 
mass vaccination centre). Based on these vaccine char-
acteristics and levels, there were 2556 possible choice tasks 
between any two hypothetical vaccines. A D-efficient 
experi mental design was used to reduce these choice tasks 
down to eight tasks with 16 hypothetical vaccines 
(appendix p 9). An example of a choice task is provided in 
table 1. Participants completed a series of eight tasks 
(appendix p 10), choosing in each task between having 
one of two hypothetical vaccines (ie, only one vaccine, not 
both, could be selected) or no vaccination.
Outcome
The study outcome was COVID-19 vaccine acceptance in 
the working-age population in France. For the purpose of 
this study, we considered the population to contain two 
groups: those who would never choose to be vaccinated, 
regardless of vaccine characteristics (outright vaccination 
refusal); and those who are hesitant and whose choice to 
See Online for appendix
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be vaccinated depends on vaccine characteristics. In our 
survey experiment, outright vaccination refusal was identi-
fied by serial non-vaccination in all eight choice tasks.
Statistical analysis
Full details on sample size calculation are provided in 
the appendix (p 2). We calculated the minimum sample 
size based on the assumption that COVID-19 vaccine 
acceptance is 50%. To estimate the probability of vac-
cine acceptance within 4% of the true value with a CI 
of 95%, based on each respondent completing eight 
choices, the minimum sample size was 300. Assuming 
10% exclusions due to previous infection and to allow 
for random allocation in the full factorial design (three 
blocks on herd immunity × two blocks on GP advice 
on vaccination), the survey sample size was set to 
2000 participants.27
We applied a single-hurdle repeated discrete choice 
model to account for a partition of the population 
between outright vaccine refusal and vaccine hesitancy 
in our data.28 The behavioural model is a two-part model 
that specifies one decision process underlying outright 
vaccination refusal and another decision process under-
lying vaccine hesitancy. The probability of outright 
vaccination refusal and associated factors was analysed 
with use of a logit regression model in the whole sample. 
The probability of vaccine acceptance based on vaccine 
characteristics and other factors was analysed with a 
conditional logit regression model for repeated discrete 
choices in the subsample of hesitant participants. 
Altogether, the two-part model provides an estimation of 
COVID-19 vaccine acceptance in the whole sample—
ie, (1 – poutright vaccination refusal) × pvaccine acceptance.
The same set of independent factors was used to explain 
both decision processes and included the following: seven 
stratification variables used in the sampling procedure 
(gender, age group, educational level, household size 
[number of adults and number of children], area of 
residence, and region of residence), 12 variables related to 
vaccination behaviour (working status, health-care worker 
status, compliance with recommended vaccinations in the 
past, risk factors for severe COVID-19 [five variables, as 
detailed above], experience of COVID-19 [three variables], 
and perceived severity of COVID-19 if infected),18,29 and 
the randomised information blocks. Compliance with 
recommended vaccinations in the past referred to vaccina-
tion for tetanus or before travelling abroad. Past com-
pliance with recommended vaccinations was highly 
corre lated with past immunisation behaviours against 
seasonal influenza or influenza A(H1N1)pdm09, which 
were discarded to avoid problems of multicollinearity 
(appendix p 3).
Probabilities and 95% CIs of outright vaccination refusal, 
vaccine acceptance in hesitant participants, and COVID-19 
vaccine acceptance in the whole sample were estimated at 
the sample mean for 12 realistic vaccination scenarios 
based on the following: vaccine efficacy (50%26 or 90%9,10), 
the risk of serious side-effects that could be assessable at 
different vaccination time points (detection threshold of 
1 in 10 000 in vaccine phase 3 trials9,10 or 1 in 100 000 shortly 
after the launch of worldwide vaccination campaigns), the 
location of the vaccine manufacturer (China, the USA, or 
the EU),11 and vaccination in mass vaccination centres with 
a herd immunity target of more than 50% of adults aged 
18–64 years old but no opinion of GPs on vaccination.18 
Probabilities and 95% CIs were similarly estimated after 
stratification by age group.
All analyses were based on two-sided p values, with 
p<0·05 considered to indicate statistical significance. 
The single-hurdle repeated discrete choice model was 
estimated with use of maximum likelihood techniques 
with R statistical software (version 3.6.3; appendix p 11).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
Of 2000 participants who were invited to and completed the 
online survey between June 22 and July 3, 2020, 58 (2·9%) 
reported previous SARS-CoV-2 infection and were exclu ded 
from the experiment. The remaining study sample 
(n=1942) was representative of adults aged 18–64 years 
resid ing in France, according to gender, age group, 
education level, household size, area of residence, and region 
Vaccination scenario A Vaccination scenario B No vaccination
Risk of being infected with SARS-CoV-2 The vaccine reduces your risk of having 
COVID-19 by 90% and reduces the risk of 
people around you becoming infected
The vaccine reduces your risk of 
having COVID-19 by 80% and 
reduces the risk of people around 
you becoming infected
Your risk of having COVID-19 
depends on the number of cases in 
your area and the protective 
measures you take on a daily basis
Risk of rare but serious side-effects 
from the vaccine
1 in 100 000 vaccinated people 1 in 10 000 vaccinated people No risk
Location of vaccine manufacturer Headquarters in the EU Headquarters in the USA Not applicable
Place of vaccine administration At your local pharmacy At a mass vaccination centre Not applicable
Choice* I would be vaccinated in scenario A I would be vaccinated in scenario B I would not be vaccinated
*Participants were asked to choose between receiving one of two vaccines or no vaccination.
Table 1: Choice task example in the discrete choice experiment
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of residence (table 2). In block 1, 652 (33·6%) participants 
were randomly allocated to receive information stating that 
more than 50% of adults aged 18–64 years old must be 
immunised (either by vaccination or infection) to reach 
herd immunity, 649 (33·4%) received information that 
more than 50% of adults must be immunised (either by 
vaccination or infection) to reach herd immunity; and 
641 (33·0%) received no information on herd immunity. In 
block 2, 972 (50·1%) participants were randomly assigned 
to receive information stating that their GP recommended 
vaccination and 970 (49·9%) were told that their GP had no 
opinion on vaccination. Participants were evenly distributed 
across all groups in each block.
560 (28·8%) participants were identified as refusing 
COVID-19 vaccination outright (table 2). In univariate 
analyses, outright vaccination refusal showed strongest 
associations (p<0·0001) with female gender, age (with an 
inverted U-shaped relationship), lower educational level, 
poorer compliance with recommended vaccinations in 
the past, no reported chronic condition (excluding hyper-
tension), and lower perceived severity of COVID-19 if 
infected (table 2). Outright vaccination refusal was not 
associated with information blocks on the collective 
benefits of herd immunity (p=0·27) or GP’s recom-
mendation on vaccination (p=0·79).
Similar associations were found in the multivariate 
analysis (table 3). In particular, participants who never 
complied with recommended vaccinations in the past were 
significantly more likely to refuse any COVID-19 vaccine 
compared with those who always complied (adjusted odds 
ratio [OR] 5·59 [95% CI 4·03–7·79], p<0·0001). By contrast, 
participants who perceived COVID-19 as very severe 
if infec ted were significantly less likely to refuse any 
COVID-19 vaccine compared with participants who 
perceived COVID-19 as not severe at all (0·31 [0·18–0·55], 
p=0·0001).
Among participants who did not refuse vaccination 
outright (1382 [71·2%]), vaccine hesitancy showed 
dependence on all the assessed vaccine characteristics, 
including vaccine efficacy and the location of the vaccine 
manufacturer (table 3). In this regard, the reduction of 
vaccine hesitancy for 90% (vs 50%) vaccine efficacy 
(OR 0·40 [95% CI 0·38–0·42], p<0·0001) was entirely 
offset if the vaccine was made in China rather than 
the EU (2·87 [2·42–3·52], p<0·0001). Vaccine hesitancy 
was significantly reduced with a 1 in 100 000 risk of seri -
ous side-effects compared with a 1 in 10 000 risk 
(0·61 [0·56–0·66], p<0·0001), and with vaccination at 
a GP practice (0·80 [0·76–0·84], p<0·0001) or local 
pharmacy (0·81 [0·76–0·86], p<0·0001) compared with at 
a mass vaccination centre. In addition, vaccine hesitancy 
significantly decreased with communication about the 
collective benefits of herd immunity (vs no information), 
especially with a herd immunity target of more than 50% 
of adults aged 18–64 years (0·76 [0·70–0·85], p<0·0001; 
table 3). By contrast, GP’s advice on vaccination was not 
significantly associated with vaccine hesitancy (p=0·67).
All participants 
(n=1942)
Outright refusal of COVID-19 
vaccination
Yes (n=560) No (n=1382) p value
Survey stratification variables
Gender ·· ·· ·· <0·0001
Female 993 (51·1%) 343 (34·5%) 650 (65·5%) ··
Male 949 (48·9%) 217 (22·9%) 732 (77·1%) ··
Age, years ·· ·· ·· <0·0001
18–24 257 (13·2%) 51 (19·8%) 206 (80·2%) ··
25–34 391 (20·1%) 143 (36·6%) 248 (63·4%) ··
35–44 427 (22·0%) 131 (30·7%) 296 (69·3%) ··
45–54 448 (23·1%) 132 (29·5%) 316 (70·5%) ··
55–64 419 (21·6%) 103 (24·6%) 316 (75·4%) ··
Educational level ·· ·· ·· <0·0001
Some high school 854 (44·0%) 301 (35·2%) 553 (64·8%) ··
High school graduate 420 (21·6%) 116 (27·6%) 304 (72·4%) ··
University graduate 668 (34·4%) 143 (21·4%) 525 (78·6%) ··
Number of adults in household ·· ·· ·· 0·077
1 453 (23·3%) 144 (31·8%) 309 (68·2%) ··
2 1038 (53·5%) 303 (29·2%) 735 (70·8%) ··
≥3 451 (23·2%) 113 (25·1%) 338 (74·9%) ··
Number of children in household ·· ·· ·· 0·045
0 1125 (57·9%) 298 (26·5%) 827 (73·5%)
1 379 (19·5%) 121 (31·9%) 258 (68·1%)
2 265 (13·6%) 81 (30·6%) 184 (69·4%)
≥3 173 (8·9%) 60 (34·7%) 113 (65·3%)
Area of residence ·· ·· ·· 0·21
Rural area 433 (22·3%) 138 (31·9%) 295 (68·1%) ··
Urban area of <100 000 inhabitants 580 (29·9%) 169 (29·1%) 411 (70·9%) ··
Urban area of ≥100 000 inhabitants 929 (47·8%) 253 (27·2%) 676 (72·8%) ··
Region of residence ·· ·· ·· 0·34
Île-de-France (including Paris) 373 (19·2%) 94 (25·2%) 279 (74·8%) ··
Northwest 441 (22·7%) 127 (28·8%) 314 (71·2%) ··
Northeast 436 (22·5%) 139 (31·9%) 297 (68·1%) ··
Southwest 214 (11·0%) 60 (28·0%) 154 (72·0%) ··
Southeast 478 (24·6%) 140 (29·3%) 338 (70·7%) ··
Variables related to vaccination behaviour
Working status ·· ·· ·· 0·15
Worker in the private sector 830 (42·7%) 220 (26·5%) 610 (73·5%) ··
Worker in the public sector 411 (21·2%) 125 (30·4%) 286 (69·6%) ··
Not working 701 (36·1%) 215 (30·7%) 486 (69·3%) ··
Health-care worker ·· ·· ·· 0·39
Yes 124 (6·4%) 40 (32·3%) 84 (67·7%) ··
Not reported 1818 (93·6%) 520 (28·6%) 1298 (71·4%) ··
Compliance with recommended 
vaccinations in the past
·· ·· ·· <0·0001
Always 989 (50·9%) 182 (18·4%) 807 (81·6%) ··
Sometimes 711 (36·6%) 237 (33·3%) 474 (66·7%) ··
Never 242 (12·5%) 141 (58·3%) 101 (41·7%) ··
Current pregnancy (among women) ·· ·· ·· 0·64
Yes 23 (2·3%) 9 (39·1%) 14 (60·9%) ··
Not reported 970 (97·7%) 334 (34·4%) 636 (65·6%) ··
(Table 2 continues on next page)
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Similar to outright vaccination refusal, independent 
predictors of vaccine hesitancy included female gender, 
age (with an inverted U-shaped relationship), lower 
educational level, poor compliance with recommended 
vaccinations in the past, and no reported hypertension (as 
a chronic condition; table 3). In contrast to vaccination 
refusal, vaccine hesitancy was not associated with the 
perceived severity of COVID-19 if infected, but was signi-
ficantly decreased with working status (vs not working) 
and experience of COVID-19 (having had symptoms or 
knowing someone with COVID-19), and was increased in 
the southeast region versus Île-de-France.
In the context of a mass vaccination campaign with 
vaccine administration in mass vaccination centres and 
communication about the collective benefits of herd 
immunity, the behavioural model predicted that outright 
refusal of COVID-19 vaccination would be present in 
29·4% (95% CI 28·6–30·2) of the working-age population 
in France (appendix p 12). Furthermore, COVID-19 
vaccine hesitancy would be maximised for a vaccine 
manufactured in China with 50% efficacy and a risk of 
serious side-effects detectable at a 1 in 10 000 threshold, 
resulting in 27·4% (26·8–28·0) vaccine acceptance 
(figure 1; appendix p 12). By contrast, COVID-19 vaccine 
hesitancy would be minimised for a vaccine manufactured 
in the EU with 90% efficacy and a risk of serious side-
effects detectable at a lower threshold of 1 in 100 000, 
resulting in 61·3% (60·5–62·1) vaccine acceptance 
(figure 1; appendix p 12). As both outright vaccination 
refusal and vaccine hesitancy were associated with 
age with an inverted U-shaped relation ship, COVID-19 
vaccine acceptance would be maxi mised at both ends 
of the age spectrum in the working-age population 
(18–24 years 68·4% [66·7–70·1]; 55–64 years 68·1% 
[66·5–69·8]; figure 2).
Discussion
This study shows that COVID-19 vaccination intentions 
in the French working-age population depend on the 
characteristics of new vaccines and the national vaccina-
tion strategy, among many other factors. In this survey 
experi ment, COVID-19 vaccination intentions were 
assessed from repeated choice tasks among vaccines with 
varying characteristics. Accordingly, we developed a 
behavioural model that allowed us to disentangle outright 
vaccination refusal (serial non-vaccination regardless of 
vaccine characteristics) from vaccine hesitancy (vaccine 
acceptance based on vaccine characteristics).19 As of early 
July, 2020, 29% of the French working-age population 
would refuse any COVID-19 vaccine, 27% would accept 
COVID-19 vaccines provided in mass vaccination centres, 
even with less favourable characteristics (vaccine efficacy 
at 50% and risk of serious side-effects at 1 in 10 000) 
and a manufacturer based in China, and 43% would 
remain hesitant unless COVID-19 vaccines had better 
characteristics or were manufactured in the USA or EU. 
Both outright vaccination refusal and vaccine hesitancy 
showed independent associ ations with age with an 
inverted U-shaped relationship, suggesting that con-
sidera tion should be given to increasing the priority level 
All participants 
(n=1942)
Outright refusal of COVID-19 
vaccination
Yes (n=560) No (n=1382) p value
(Continued from previous page)
Smoking status ·· ·· ·· 0·73
Former or current smoker 1129 (58·1%) 329 (29·1%) 800 (70·9%) ··
Never smoker 813 (41·9%) 231 (28·4%) 582 (71·6%) ··
Body-mass index, kg/m² ·· ·· ·· 0·35
≥30 (obese) 346 (17·8%) 92 (26·6%) 254 (73·4%) ··
25 to <30 (overweight) 569 (29·3%) 158 (27·8%) 411 (72·2%) ··
<25 (normal weight) 1027 (52·9%) 310 (30·2%) 717 (69·8%) ··
Hypertension ·· ·· ·· 0·037
Yes 165 (8·5%) 36 (21·8%) 129 (78·2%) ··
Not reported 1777 (91·5%) 524 (29·5%) 1253 (70·5%) ··
Chronic condition other than hypertension* ·· ·· ·· <0·0001
Yes 236 (12·2%) 39 (16·5%) 197 (83·5%) ··
Not reported 1706 (87·8%) 521 (30·5%) 1185 (69·5%) ··
Had COVID-19 symptoms with no medical 
confirmation
·· ·· ·· 0·048
Yes 362 (18·6%) 89 (24·6%) 273 (75·4%) ··
Not reported 1580 (81·4%) 471 (29·8%) 1109 (70·2%) ··
Had a negative test for SARS-CoV-2 
infection
·· ·· ·· 0·65
Yes 50 (2·6%) 13 (26·0%) 37 (74·0%) ··
Not reported 1892 (97·4%) 547 (28·9%) 1345 (71·1%) ··
Knows someone who had COVID-19 ·· ·· ·· 0·0039
Yes, with hospital admission 295 (15·2%) 68 (23·1%) 227 (76·9%) ··
Yes, without hospital admission 522 (26·9%) 136 (26·1%) 386 (73·9%) ··
Not reported 1125 (57·9%) 356 (31·6%) 769 (68·4%) ··
Perceived severity of COVID-19 if infected ·· ·· ·· <0·0001
Very severe 235 (12·1%) 42 (17·9%) 193 (82·1%) ··
Somewhat severe 688 (35·4%) 163 (23·7%) 525 (76·3%) ··
Not particularly severe 631 (32·5%) 183 (29·0%) 448 (71·0%) ··
Not severe at all 105 (5·4%) 49 (46·7%) 56 (53·3%) ··
Do not know 283 (14·6%) 123 (43·5%) 160 (56·5%) ··
Background information on COVID-19 vaccination
Herd immunity against SARS-CoV-2 ·· ·· ·· 0·27
>50% of adults aged 18–64 years old must 
be immunised (either by vaccination or 
infection) to reach herd immunity
652 (33·6%) 193 (29·6%) 459 (70·4%) ··
>50% of adults must be immunised 
(either by vaccination or infection) to 
reach herd immunity
649 (33·4%) 197 (30·4%) 452 (69·6%) ··
No information 641 (33·0%) 170 (26·5%) 471 (73·5%) ··
General practitioner’s advice on vaccination ·· ·· ·· 0·79
Vaccination recommended 972 (50·1%) 283 (29·1%) 689 (70·9%) ··
No opinion 970 (49·9%) 277 (28·6%) 693 (71·4%) ··
Data are n (%); percentages represent the distribution of variable categories among all participants or the split between 
outright refusal and no outright refusal of vaccination for participants in each category. p values are from χ2 test. 
*Diabetes (86 [36%] of 236 participants), asthma (88 [37%]), chronic lung disease other than asthma (47 [20%]), 
chronic arterial disease (13 [6%]), chronic heart disease (26 [11%]), chronic kidney disease (six [3%]), or cancer (21 [9%]).
Table 2: Characteristics and outright refusal of COVID-19 vaccination among study participants
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for vaccination of the youngest adults at high risk of 
SARS-CoV-2 transmission.
The study findings shed new light on anti-COVID-19 
vaccination behaviour and its underlying mechanisms. 
Two results suggest that the outright vaccination refusal 
measured in this study is a good proxy of anti-COVID-19 
vaccination behaviour. Outright vaccination refusal is 
associated with a high level of decision-making certainty: 
participants refused all 16 hypothetical vaccines with 
varying characteristics (appendix p 10). The double-hurdle 
model28 showed that a negligible proportion of those 
participants would accept vaccination even if presented 
with an ideal vaccine on all four characteristics (data not 
shown). Furthermore, we found no association between 
Outright refusal of COVID-19 
vaccination (n=560)
COVID-19 vaccine hesitancy  
(n=1382)
OR (95% CI) p value OR (95% CI) p value
Vaccine characteristics
Efficacy
50% ·· ·· 1 (ref) ·
80% ·· ·· 0·70 (0·65–0·77) <0·0001
90% ·· ·· 0·40 (0·38–0·42) <0·0001
100% ·· ·· 0·36 (0·35–0·37) <0·0001
Risk of serious side-effects
1 in 10 000 ·· ·· 1 (ref) ··
1 in 100 000 ·· ·· 0·61 (0·56–0·66) <0·0001
Region of vaccine manufacturer
EU ·· ·· 1 (ref) ··
China ·· ·· 2·87 (2·42–3·52) <0·0001
USA ·· ·· 1·86 (1·64–2·15) <0·0001
Place of vaccination administration
Mass vaccination centre ·· ·· 1 (ref) ··
General practitioner’s practice ·· ·· 0·80 (0·76–0·84) <0·0001
Local pharmacy ·· ·· 0·81 (0·76–0·86) <0·0001
Background information on COVID-19 vaccination
Herd immunity against SARS-CoV-2
No information 1 (ref) ·· 1 (ref) ··
>50% of adults aged 18–64 years old must be immunised (either 
by vaccination or infection) to reach herd immunity
1·14 (0·87–1·48) 0·35 0·76 (0·70–0·85) <0·0001
>50% of adults must be immunised (either by vaccination or 
infection) to reach herd immunity
1·16 (0·89–1·51) 0·28 0·82 (0·75–0·92) 0·0024
General practitioner’s advice on vaccination
No opinion 1 (ref) ·· 1 (ref) ··
Vaccination recommended 1·01 (0·81–1·25) 0·95 1·02 (0·92–1·15) 0·67
Survey stratification variables
Gender
Female 1 (ref) ·· 1 (ref) ··
Male 0·57 (0·46–0·72) <0·0001 0·82 (0·75–0·90) 0·0002
Age, years
18–24 1 (ref) ·· 1 (ref) ··
25–34 1·99 (1·30–3·09) 0·0017 1·37 (1·09–1·84) 0·0011
35–44 1·85 (1·19–2·90) 0·0066 1·17 (0·95–1·52) 0·13
45–54 1·92 (1·25–3·00) 0·0035 0·91 (0·77–1·11) 0·37
55–64 1·67 (1·07–2·61) 0·025 0·72 (0·63–0·84) 0·0014
Educational level
Some high school 1 (ref) ·· 1 (ref) ··
High school graduate 0·75 (0·56–1·00) 0·054 0·99 (0·87–1·15) 0·88
University graduate 0·55 (0·41–0·72) <0·0001 0·86 (0·77–0·97) 0·029
Number of adults in household 0·95 (0·80–1·12) 0·51 1·00 (0·92–1·08) 0·94
Number of children in household 1·08 (0·96–1·22) 0·17 1·04 (0·98–1·10) 0·20
(Table 3 continues on next page)
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Outright refusal of COVID-19 
vaccination (n=560)
COVID-19 vaccine hesitancy  
(n=1382)
OR (95% CI) p value OR (95% CI) p value
(Continued from previous page)
Area of residence
Rural area 1 (ref) ·· 1 (ref) ··
Urban area of <100 000 inhabitants 0·85 (0·63–1·14) 0·28 1·00 (0·87–1·18) 0·96
Urban area of ≥100 000 inhabitants 0·94 (0·70–1·26) 0·66 1·10 (0·95–1·31) 0·21
Region of residence
Île-de-France (including Paris) 1 (ref) ·· 1 (ref) ··
Northwest 1·13 (0·78–1·65) 0·52 1·09 (0·91–1·36) 0·34
Northeast 1·26 (0·88–1·81) 0·21 1·11 (0·93–1·38) 0·26
Southwest 1·03 (0·66–1·59) 0·90 1·14 (0·92–1·49) 0·22
Southeast 1·15 (0·81–1·63) 0·43 1·34 (1·10–1·72) 0·0005
Variables related to vaccination behaviour
Working status
Not working 1 (ref) ·· 1 (ref) ··
Worker in the private sector 0·91 (0·69–1·20) 0·51 0·79 (0·71–0·88) 0·0004
Worker in the public sector 1·12 (0·81–1·55) 0·48 0·82 (0·73–0·95) 0·017
Health-care worker
Not reported 1 (ref) ·· 1 (ref) ··
Yes 1·25 (0·79–1·94) 0·33 1·18 (0·93–1·62) 0·14
Compliant with recommended vaccination in the past
Always 1 (ref) ·· 1 (ref) ··
Sometimes 2·17 (1·72–2·76) <0·0001 1·76 (1·47–2·19) <0·0001
Never 5·59 (4·03–7·79) <0·0001 2·08 (1·49–3·44) <0·0001
Current pregnancy
Not reported 1 (ref) ·· 1 (ref) ··
Yes 1·10 (0·42–2·73) 0·84 1·45 (0·89–3·93) 0·096
Smoking status
Never smoker 1 (ref) ·· 1 (ref) ··
Former or current smoker 0·80 (0·64–1·01) 0·057 0·94 (0·85–1·05) 0·30
Body-mass index, kg/m²
<25 (normal weight) 1 (ref) ·· 1 (ref) ··
25 to <30 (overweight) 0·93 (0·72–1·19) 0·56 1·02 (0·91–1·18) 0·70
≥30 (obese) 0·80 (0·59–1·10) 0·18 1·01 (0·87–1·19) 0·94
Hypertension
Not reported 1 (ref) ·· 1 (ref) ··
Yes 1·14 (0·72–1·78) 0·57 0·72 (0·62–0·87) 0·0065
Chronic condition other than hypertension
Not reported 1 (ref) ·· 1 (ref) ··
Yes 0·60 (0·40–0·87) 0·0088 1·05 (0·90–1·25) 0·55
Had COVID-19 symptoms with no medical confirmation
Not reported 1 (ref) ·· 1 (ref) ··
Yes 0·80 (0·60–1·07) 0·13 0·85 (0·76–0·96) 0·017
Had a negative test for SARS-CoV-2 infection
Not reported 1 (ref) ·· 1 (ref) ··
Yes 0·90 (0·42–1·78) 0·76 1·03 (0·77–1·57) 0·85
Knows someone who had COVID-19
Not reported 1 (ref) ·· 1 (ref) ··
Yes, with hospital admission 0·86 (0·66–1·12) 0·28 0·89 (0·80–1·00) 0·062
Yes, without hospital admission 0·78 (0·56–1·08) 0·14 0·73 (0·66–0·83) 0·0001
(Table 3 continues on next page)
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out right vaccination refusal and other experi mental 
variables (collective benefits of herd immunity or recom-
mendation of vaccination by the GP).
We found that anti-COVID-19 vaccination behaviour 
was strongly associated with certain characteristics of the 
partici pants: female gender, age with an inverted U-shaped 
relation ship, lower educational level, poorer compliance 
with recommended vaccinations in the past, no report 
of a chronic condition, and lower perceived severity of 
COVID-19 if infected. These results corroborate other 
studies’ findings on the determinants of COVID-19 vaccine 
hesitancy, in particular female gender12,14–16,30 and lower edu-
c ational level.12,15,30 Other attitudinal character istics sug gest 
the exacer bation of underlying vaccine hesitancy mech-
anisms in anti-COVID-19 vaccination behaviour, namely 
distrust in vaccination and vaccination complacency.19
Outright vaccination refusal implies that people refused 
all four hypothetical vaccines that had 100% efficacy 
(appendix p 10) and all eight hypothetical vaccines that 
had the lowest risk of serious side-effects (1 in 100 000), 
which corresponds to a detection threshold that cannot be 
reached in vaccine phase 3 trials that have enrolled fewer 
than 100 000 people.9,10 These findings suggest distrust in 
the effectiveness and safety of new COVID-19 vaccines. 
Outright vaccination refusal was also associated with 
lower compliance with immunisation in the past, 
reflecting the anchoring effect of negative attitudes 
towards vaccination in France and distrust in vaccine 
safety in particular.18,21,31 Other studies on COVID-19 
vaccination intentions found that concern about vaccine 
safety was the main reason for refusing vaccination in 
France.14,15 A more general distrust in health policy and 
Outright refusal of COVID-19 
vaccination (n=560)
COVID-19 vaccine hesitancy  
(n=1382)
OR (95% CI) p value OR (95% CI) p value
(Continued from previous page)
Perceived severity of COVID-19 if infected
Not severe at all 1 (ref) ·· 1 (ref) ··
Very severe 0·31 (0·18–0·55) 0·0001 1·10 (0·83–1·65) 0·52
Somewhat severe 0·38 (0·24–0·62) 0·0001 0·91 (0·73–1·21) 0·49
Not particularly severe 0·50 (0·32–0·80) 0·0037 1·11 (0·86–1·58) 0·44
Do not know 0·76 (0·46–1·25) 0·28 1·07 (0·82–1·57) 0·64
ORs and 95% CIs were estimated simultaneously with use of a two-part model to disentangle outright refusal of COVID-19 vaccination in the whole sample and COVID-19 
vaccine acceptance in the subsample of hesitant participants. Results of the second part of the model (ie, vaccine hesitancy) represent odds of refusal of COVID-19 vaccines 
(rather than acceptance of COVID-19 vaccines). OR=odds ratio.
Table 3: Behavioural model of COVID-19 vaccination intentions
Figure 1: COVID-19 vaccine acceptance predicted in the French working-age population depending on vaccine efficacy, vaccine safety, and location of vaccine manufacturer












































































































Outright vaccine refusal Vaccine hesitancy Vaccine acceptance
Risk of serious side-effects 1 in 100 000
Vaccine efficacy 50%
Risk of serious side-effects 1 in 10 000 Risk of serious side-effects 1 in 100 000
Vaccine efficacy 90%
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services12,14–16 was also suggested by three of our findings: 
the outright refusal of COVID-19 vaccination regardless 
of the country of the manufacturer, where the vaccina-
tion is given, and whether or not the GP recommends 
vaccination. Future studies should explicitly consider the 
role of trust in outright vaccination refusal and vaccine 
hesitancy.
In accordance with other studies on COVID-19 
vaccination intentions,12,14,15 we found that vaccination 
complacency might fuel anti-COVID-19 vaccination 
behaviour, as outright vaccination refusal was strongly 
associated with a lower perceived severity of COVID-19 if 
infected and the absence of a reported chronic condition. 
Given concerns about vaccine safety in this group, the 
individual benefit–risk assessment of COVID-19 vacci-
nation might be perceived as unfavourable. The risk of 
developing a severe form of COVID-19 is low in the 
working-age population and very low in adults younger 
than 50 years.3–5 Although the death toll from COVID-19 
amounted to 50 000 deaths after the peak of the second 
wave of the epidemic in France, 553 (1·1%) of these deaths 
were recorded in people younger than 50 years of age (as 
of Nov 26, 2020),32 and were most likely attributable to 
underlying chronic conditions.5 Although the individual 
benefit–risk balance could be assessed more broadly, 
we found that outright vaccination refusal was insen-
sitive to communication about both the individual and 
societal benefits of herd immunity as a way to return to a 
normal life.
COVID-19 vaccine hesitancy was sensitive to all four 
characteristics presented for the hypothetical vaccines. 
Hesitancy decreased with higher vaccine efficacy and 
lower risk of serious side-effects, and increased if 
vaccination was only accessible in mass vaccination 
centres rather than a GP practice or local pharmacy.18 
Recommendation of vaccination by the GP would not be 
enough to compensate for COVID-19 vaccine hesitancy 
related to mass vaccination centres.18 The lack of 
significance of the GP’s recommendation on vaccine 
accep tance might be because the related randomised 
statement (only one sentence) was presented before the 
discrete choice experiment (appendix p 6) and because 
four of eight choice tasks included a direct comparison of 
vaccination at GP practice versus mass vaccination centres 
(appendix p 10). Accordingly, vaccination at GP practice 
might have captured the expected effect of a GP’s recom-
mendation on vaccine acceptance. COVID-19 vaccine 
hesitancy increased if the vaccine manufacturer was not 
from the EU; the effect of 80% or even 90% (vs 50%) 
vaccine efficacy on hesitancy was entirely offset if the 
vaccine was made in the USA or China. Such distrust in 
foreign COVID-19 vaccines could be explained by the 
perception of rushed vaccine development, as made 
explicit by Operation Warp Speed in the USA,12,14,15 or a 
more profound distrust of Chinese products since the 
beginning of the SARS-CoV-2 pandemic.16,17
Finally, this survey experiment provides causal evidence 
that communicating the collective benefits of herd 
immunity in terms of a herd immunity target is associated 
with significantly reduced COVID-19 vaccine hesitancy 
in the working-age population, confirming previous 
findings based on fictitious epidemics.24 This finding is 
important in the context of the COVID-19 pandemic 
because the working-age population accounts for the 
Figure 2: COVID-19 vaccine acceptance predicted in the French working-age population depending on age group, vaccine efficacy, vaccine safety, and location of vaccine manufacturer
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majority (58%) of the French population (French census 
on Jan 1, 2020) and herd immunity can only be reached 
if COVID-19 vaccine acceptance is substantial in this 
group.6,8 In this study, COVID-19 vaccine acceptance was 
highest at both ends of the working-age spectrum, among 
the youngest adults at highest risk of SARS-CoV-2 
infection7 and the oldest adults at highest risk of a severe 
form of COVID-19.4 These findings suggest that a strict 
COVID-19 vaccination prioritisation based on age from 
oldest to youngest adults23 could miss a major opportunity 
to achieve herd immunity more quickly by vaccinat ing the 
youngest adults who are very likely to accept vaccination. 
A strategy prioritising vaccination in the younger popu-
lation, after those aged 50 years and older, could alleviate 
physical distancing measures in young adults who are at a 
very low risk of a severe form of COVID-19.6,23
The main limitation of our study is the timing of the 
survey in early July, 2020. At this time, there was little 
information about COVID-19 candidate vaccines and 
vaccination locations, and people’s vaccination intentions 
might have evolved over time with new information. 
Nevertheless, a full page of background information on 
COVID-19 vaccination was presented (appendix p 6), 
providing common background informa tion to all 
respondents (who were also randomly allocated to the 
two information blocks). This design should control for 
much of the information that people have become aware 
of over time. The vaccine characteristics presented in the 
survey experiment represent four salient char acteristics 
expected to be associated with COVID-19 vaccine hesitancy 
(efficacy, safety, country of the vaccine manufacturer, and 
place of vaccine administration). Other vaccine char-
acteristics not included in this study are the risk of minor 
side-effects and duration of vaccine immunity; however, 
another study suggested that these factors would be less 
relevant to decision making than the factors we included 
in our study.17 In early July, 2020, the French population 
was recovering from the first wave of SARS-CoV-2 and 
some of the most stringent physical distancing measures 
in Europe.2 People’s benefit–risk assessment of COVID-19 
vaccination might have evolved over time in response to 
rising numbers of SARS-CoV-2 infections, reintroduced 
physical distancing measures since Oct 30, 2020,2 the 
approval of COVID-19 candidate vaccines with higher than 
90% efficacy,9,10 and vaccine safety concerns (eg, allergic 
reactions) that might not be captured by the presen tation 
of absolute risks of serious side-effects. Additionally, the 
types of places that could be used for mass vaccination 
centres were not specified in the survey experiment. 
Respondents’ interpretations of this feature might evolve 
as the location of mass vaccina tion centres is announced 
and further influence COVID-19 vaccine acceptance.
Another possible limitation is that we identified outright 
vaccination refusal as refusal to be vaccinated in all eight 
choice tasks, regardless of vaccine characteristics. This 
response pattern could also represent a fast way for 
respondents to complete the tasks; however, this behaviour 
is not commonly observed in discrete choice experiments.33 
Furthermore, our results have content validity and are 
consistent with other studies of COVID-19 vaccination 
intentions that used different methods.12 A further limita-
tion is that the death toll has been even more pronounced 
in those aged 50 years or older32 during the second wave 
compared with the first wave of SARS-CoV-2. As a result, 
the perceived severity of COVID-19 among the working-
age population could either remain stable or decrease, 
which might reduce vaccine acceptance. Further more, as 
the start of a mass vaccination campaign draws nearer, the 
antivaccine movement could become more active, as sug-
gested by an upward trend in COVID-19 vaccine hesitancy 
before November, 2020.12,15 The dynam ics of anti-COVID-19 
vaccination behaviour should be closely monitored.
In summary, this survey experiment shows that 
COVID-19 vaccine acceptance in the working-age popula-
tion depends on the characteristics of new vaccines and 
the national vaccination strategy, among many other 
factors. Acceptance of the first-in-race vaccines using an 
mRNA platform9,10 is likely to be lower than expected in 
France because logistical and cold storage constraints 
might require mass vaccination centres, the vaccine is 
designated as an American vaccine9,10 rather than German 
technology,9 and the national vaccination strategy priori-
tises the self-protection of older adults rather than herd 
immunity in the whole adult population.23 Whether or not 
the objective of a national vaccination strategy becomes 
herd immunity, our results suggest that it would be more 
successful in France with COVID-19 vaccines made in 
the EU and with a communication strategy emphasising 
the collective benefits of herd immunity in the working-
age population.
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